USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SEACHANGE PHARMACEUTICALS, INC.
Address:
3031 Tisch Way
SAN JOSE, CA 95128-2532
EIN:
127053077
DUNS:
831344416
Number of Employees:
2
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $753,966.00 3
SBIR Phase II $909,637.00 1

Award List:

Drug Repurposing using Pharmacological Networks

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$202,500.00
Agency:
HHS
Principal Investigator:
Michael J. Keiser
Abstract:
DESCRIPTION (provided by applicant): Three ideas motivate this project. First, bioactive small molecules often act on multiple targets- sometimes this polypharmacology is key to their efficacy, sometimes it is the source of unwanted side-effects, rarely is it entirely absent. Second, these… More

Calculating target bias in small molecules for library design

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$250,241.00
Agency:
HHS
Principal Investigator:
Michael J. Keiser – 415-937-1732
Abstract:
DESCRIPTION (provided by applicant): Goals: The goal is to develop a computational system to predict the targets toward which small molecules are biased. The tool will optimize biased libraries, prioritize them for testing against particular targets, identify targets in phenotypic screens, and allow… More

Relating GPCRs by biased ligands for enhanced therapeutic efficacy

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$301,225.00
Agency:
HHS
Principal Investigator:
Michael J. Keiser – 415-937-7732
Abstract:
DESCRIPTION (provided by applicant): Goals: The goal is to expand the known pharmacological relationships among arrestin and G protein biased ligands. Starting with the Gi-coupled dopamine D2 receptor (D2R), we will predict biased ligands, evaluatingour methods both retrospectively and via… More

A platform to predict side-effect targets for drugs

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$909,637.00
Agency:
HHS
Principal Investigator:
Carl N. Hodge – 415-937-7732
Abstract:
DESCRIPTION (provided by applicant): Bioactive small molecules can act on multiple targets, and these off-target activities underlie many of the adverse reactions from which drugs suffer. The motivating idea of this proposal is that these Adverse Drug Reaction (ADR) targets may be predicted… More